Keymed gears up for Hong Kong IPO

Hong Kong_adobe_12May_575
By Rashmi Kumar
12 Apr 2021

Keymed Biosciences has started laying the groundwork for a planned Hong Kong IPO by filing its initial listing documents with the city’s exchange.

The Chinese biotechnology company, which focuses on the autoimmune and oncology areas, has tapped CICC, Huatai International and Morgan Stanley as the IPO sponsors. 

Keymed focuses on the discovery and development of biological therapies, and has more than 10 drug candidates in its roster, including five in clinical ...

Already a subscriber?

Continue reading this article

Try full access to GlobalCapital

Free trial